



# The Asian Pacific Association for the Study of the Liver



## APASL

## Single Topic Conference

*Molecular and Cell Biology of the Liver:  
Recent Evolution to Clinical Application*

## Program & Final Information

**Term: September 2-3, 2021**

**City: Osaka, Japan**

**Venue: Hilton Osaka (Hybrid Meeting)**

**President: Norifumi Kawada, MD., PhD.**

Professor,  
Department of Hepatology,  
Graduate School of Medicine, Osaka City University

Supported by JSH







# **APASL Single Topic Conference 2021 Osaka**

*“Molecular and Cell Biology of the Liver:  
Recent Evolution to Clinical Application”*

**September 2-3, 2021**

**Hybrid Meeting (Onsite-Venue: Hilton Osaka)**

## **Table of Contents**

Welcome Message

Invited Guest Speakers / Chairs

Organizing Committee

Conference Information

On-Site Venue

Instruction for Oral Presentation

Instruction for Chairs

Instruction for Poster Presentation

Awards / Contact

Sponsors and Support Organization

Program at a Glance

Scientific Program

Poster Session Program

Abstracts: Meet the Expert

Abstracts: General Sessions

Abstracts: Sponsored Seminars

Abstracts: Oral Free Papers

Abstracts: Poster Free Papers



# Welcome Message

Dear colleagues,

On behalf of the Organizing Committee, it gives us great pleasure to invite you to Asian Pacific Association for the Study of the Liver Single Topic Conference (APASL STC) on the theme of “Molecular and Cell Biology of the Liver: Recent Evolution to Clinical Application”, which will be held on September 2-3, 2021 in Osaka, Japan as a Hybrid Meeting (Zoom). (This conference had been originally scheduled in September 2020, however it has been rescheduled because of the pandemic of COVID-19. We ask your understanding and cooperation.)



Chronic inflammation, cellular damage, regeneration and fibrosis are the hallmarks of chronic liver diseases. A recognition of molecular expression patterns in intrahepatic cellular sources in normal and diseased liver provides clues for understanding pathogenic pathways while studies of the structure and function of molecules implicated in liver disease provide insights into their potential as therapeutic targets.

This conference will bring together fundamental researchers and translational scientists to discuss recent successes and highlight challenges across the spectrum of emerging cellular and molecular evolutions. This conference will help to foster interactions and new connections between basic experts focused on molecular-based, cell-based regulation of liver diseases with translational scientists focused on therapeutic approaches currently in development.

The scientific program will consist of invited lectures, plenary sessions, symposia, and free papers which provide the latest information and fresh ideas for hepatologists.

The delegates of experts from all over the world are expected to attend this conference. We are sure that this will provide an excellent opportunity for those of us in the Asian Pacific region to share the latest views, values, experience and practice, and greatly contribute to this field.

We look forward to welcoming you to this exciting event, and hopefully, if the situation allows, we hope you will be able to visit our charming city of Osaka.

With warmest regards,

A handwritten signature in black ink, appearing to read 'Norifumi Kawada'. The signature is fluid and cursive, with a large initial 'N' and 'K'.

Norifumi Kawada, MD., PhD.

President of APASL STC 2021 Osaka

Professor, Department of Hepatology, Graduate School of Medicine,  
Osaka City University

## Invited Guest Speakers / Chairs

Dr. Kazuaki Chayama (Hiroshima University, Japan)  
Dr. Massimo Colombo (Liver Center IRCCS San Raffaele Hospital, Italy)  
Dr. A Kadir Dokmeci (Ankara University, Turkey)  
Dr. Ariel Feldstein (UC San Diego School of Medicine, USA)  
Dr. Junji Furuse (Kyorin University, Japan)  
Dr. Jacob George (The University of Sydney, Australia)  
Dr. Jordi Gracia-Sancho (IDIBAPS Biomedical Research Institute, Spain)  
Dr. Kiyoshi Hasegawa (The University of Tokyo, Japan)  
Dr. Eiji Hara (Osaka University, Japan)  
Dr. Lijian Hui (Shanghai Institute of Biochemistry and Cell Biology, China)  
Dr. Yutaka Inagaki (Tokai University School of Medicine, Japan)  
Dr. Tatehiro Kagawa (Tokai University School of Medicine, Japan)  
Dr. Takanori Kanai (Keio University School of Medicine, Japan)  
Dr. Jia-Horng Kao (National Taiwan University, Taiwan)  
Dr. Naoya Kato (Chiba University Hospital, Japan)  
Dr. Tatiana Kisseleva (UCSD, USA)  
Dr. Masatoshi Kudo (Kindai University, Japan)  
Dr. George Lau (Humanity and Health Medical Center, Hong Kong)  
Dr. Derek A Mann (Newcastle University, UK)  
Dr. Giuseppe Mazza (Institute for Liver and Digestive Health, University College London, UK)  
Dr. Atsushi Miyajima (The University of Tokyo, Japan)  
Dr. Hidewaki Nakagawa (RIKEN Center for Integrative Medical Sciences, Japan)  
Dr. Sadahisa Ogasawara (Chiba University, Japan)  
Dr. Hiroshi Ohno (RIKEN Center for Integrative Medical Sciences, Japan)  
Dr. Masao Omata (The University of Tokyo, Japan)  
Dr. Diana Payawal (Fatima University Medical Center, Philippines)  
Dr. Xiaolong Qi (The First Hospital of Lanzhou University, China)  
Dr. Shiv K Sarin (Institute of Liver and Biliary Sciences, India)  
Dr. Robert F Schwabe (Columbia University, USA)  
Dr. Ekihiro Seki (Cedars-Sinai Medical Center, USA)  
Dr. Gyongi Szabo (Harvard Medical School, USA)  
Dr. Tatsuhiro Shibata (National Cancer Center, Japan)  
Dr. Toshifumi Tada (Japanese Red Cross Society Himeji Hospital, Japan)  
Dr. Tetsuo Takehara (Osaka University, Japan)  
Dr. Yasuhito Tanaka (Kumamoto University, Japan)  
Dr. Hideki Taniguchi (The University of Tokyo, Japan)  
Dr. Tawesak Tanwandee (Mahidol University, Thailand)  
Dr. Hidenori Toyoda (Ogaki Municipal Hospital, Japan)  
Dr. Kaoru Tsuchiya (Musashino Red Cross Hospital, Japan)  
Dr. Vincent Wong (The Chinese University of Hong Kong, Hong Kong)  
Dr. Jin Mo Yang (The Catholic University of Korea, Korea)  
Dr. Hitoshi Yoshiji (Nara Medical University, Japan)  
Dr. Man-Fung Yuen (The University of Hong Kong, Hong Kong)

In alphabetical order

# Organizing Committee

## Local Organizing Committee

President: Dr. Norifumi Kawada	Vice-President: Dr. Atsushi Miyajima
Treasurer: Dr. Kenichi Ikejima	Treasurer: Dr. Soichi Kojima
Vice-Treasurer: Dr. Yutaka Yata	Secretary General: Dr. Kazuo Ikeda
Scientific Secretariat: Dr. Misako Matsubara	Scientific Secretariat: Dr. Le Thi Thanh Thuy

## APASL Steering Committee

Chairman of Steering Committee	Dr. Shiv Kumar Sarin (India)
President	Dr. Jin Mo Yang (Korea)
Immediate Past President	Dr. Tawesak Tanwandee (Thailand)
President Elect	Dr. Han-Chieh Lin (Taiwan)
Secretary General-cum-Treasurer	Dr. Manoj K Sharma (India)
Past Presidents	Dr. Laurentius A. Lesmana (Indonesia)
	Dr. Jose Sollano (Philippines)
	Dr. Masao Omata (Japan)
	Dr. Dong Jin Suh (Korea)
	Dr. George Lau (Hong Kong)
	Dr. Jidong Jia (China)
	Dr. Teerha Piratvisuth (Thailand)
	Dr. Jia-Horng Kao (Taiwan)
	Dr. Darrell Crawford (Australia)
	Dr. A. Kadir Dokmeci (Turkey)
	Dr. Osamu Yokosuka (Japan)
	Dr. Jinlin Hou (China)
	Dr. Barjesh Chander Sharma (India)
	Dr. Diana A. Payawal (Philippines)
	Dr. Rino Gani (Indonesia)

## APASL Executive Council

Assistant Secretary	Dr. Hong You (China)
Executive Council	Dr. Simone Strasser (Australia)
	Dr. Yaman Tokat (Turkey)
	Dr. Chun-Jen Liu (Taiwan)
	Dr. Gulnara Aghayeva (Azerbaijan)
	Dr. Mamun-Al-Mahtab (Bangladesh)
	Dr. Rakhi Maiwall (India)
	Dr. Yoshiyuki Ueno (Japan)

# Conference Information

## Registration Fee and Category

	Pre-Registration until August 31, 2021	On Site
APASL Member*	JPY 20,000	JPY 25,000
	Online: JPY 15,000	Online: JPY 20,000
Non-Member	JPY 25,000	JPY 30,000
	Online: JPY 20,000	Online: JPY 25,000
Trainee / Resident**	JPY 15,000	JPY 20,000
	Online: JPY 10,000	Online: JPY 15,000
Accepted Abstract Submitter	JPY 20,000	JPY 25,000
	Online: JPY 15,000	Online: JPY 20,000
Accompanying Person	JPY 5,000	JPY 5,000

JPY=Japanese Yen

\*APASL Members who have paid 2021 Membership Fee can apply for discounted registration fee.

\*Proof of status is required.

\*Registration for viewing of On-demand Presentation is available until September 30<sup>th</sup> 2021.

## Online Participation (Style: Zoom Webinar)

- The conference program will be presented as a hybrid style meeting.
- Attendants are able to enter the webinar through Zoom <https://zoom.us/join> with the ID and Password of which they have been informed by the conference secretariat. \* For Speakers/Chairs, the secretariat sends an individual invitation link to enter the webinar.
- The lectures will be delivered live or by recorded video. After the presentation, the discussion (Q&A) time will be held according to the moderator's instructions. Online viewers are able to send textual questions to the Q&A column, and the onsite participants may ask questions using the microphone in the conference room. We anticipate your active discussions.
- After the conference term, the recorded lectures and discussion will be distributed on-demand from the presentation page of APASL STC Osaka Website <http://www.apaslstc-osaka2021.org/index.html>  
The viewing period of the on-demand presentation is scheduled to be from September 6 through September 30, 2021. The secretariat will receive the questions by e-mail during the on-demand delivery period and will forward them to each speaker.

### [Precautions]

- The organizer cannot handle problems such as computer operation, internet connection, video connection, and audio connection. Please solve such problems by yourself. We recommend the following environment.
  - We would appreciate it if you could use a PC with as much memory as possible (CPU i5 or more, memory 8 Giga or more).
  - Please connect to the Internet via a wired LAN line as much as possible.
- To transfer or share the ID and password, recording of screens and images is strictly prohibited.
- The internet fee at this online conference will be borne by each attendant.  
We cordially solicit your understanding and cooperation.

## Onsite Registration/PC Pre-view Hours

September 2 (Thursday)      8:30-18:00 (JST)

September 3 (Friday)      8:30-18:00 (JST)



# Onsite-Venue

## Hilton Osaka

**Address:** 8-8, Umeda 1-chome, Kita-ku, Osaka,  
530-0001, Japan

**Tel:** +81-6-6347-7111

**Fax:** +81-6-6347-7001

**Location:** 2 min. walk from JR Osaka Station  
25 min. from Osaka Itami Airport by Limousine Bus  
65 min. from Kansai Airport by Limousine Bus

**URL:** <https://www3.hilton.com/en/hotels/japan/hilton-osaka-OSAHITW/maps-directions/index.html>



Conference Room: “Sakura”, 5<sup>th</sup> Floor


Registration, PC Preview Desk: In front of “Sakura”, 5<sup>th</sup> Floor

Secretariat Room: “Glass Room”, 5<sup>th</sup> Floor

Cloak: Foyer, 5<sup>th</sup> Floor

Speakers/Chairs Ready Room: “Fuji” “Kikyo”, 5<sup>th</sup> Floor

### Floor Plan Hilton Osaka



# Instruction for Oral Presentation

- An invitation email containing information about the login will be sent to the presenters/moderators through the Zoom system. The login URL will be included in the invitation email.
- We would appreciate it if you could conduct a test connection ahead of the conference.
- The general sessions' presentation time is 20 minutes. The selected Free Paper is 5 minutes.
- After presentation, the discussion time (a question-and-answer session) will be held according to the moderator's instructions.

[For those who will participate at the onsite venue]

- Please be seated at the "next speaker's seat" at least 30 minutes before the presentation.
- The slides which you have sent in advance for the presentation are prepared on the computer of the podium. Please operate the slides by yourself. Please note that the presenter tool is not available.

[For those who will attend online]

- Please join Zoom at least 30 minutes before your session begins.
- Please turn on the microphone and the camera only when you are speaking.
- The moderator will introduce the presenter at the beginning of each presentation.
- Then, the secretariat will start the presentation video. (In principle, you do not have to share your presentation by yourself.)
- After finishing the presentation, online viewers will send textual questions to the Q & A column, so please follow the moderator's instructions and answer those questions.
- The following environment is recommended.
  - Create the image resolution in XGA (1024 x 768).
  - Microsoft PowerPoint (2010-2016) can be used as the application software.
  - The fonts that come standard with Microsoft PowerPoint, Times, Arial are recommended.

[About on-demand presentation]

- The secretariat will send you questions received by e-mail and Q & A during the on-demand delivery period, so please answer them if any.

[Precautions]

- Do not post, modify, distribute or reproduce copyrighted material, trademarks, portrait rights or other property rights in any way without the prior written consent of the owners of these property rights.
- Regarding citations, please specify the source of the citation.
- Please exert caution regarding the protection of personal information such as name, age, surgery date, etc. This could lead to the identification of an individual.
- Please pay particular attention to images and videos that may be considered problematic when viewed by the public at this conference.

# Instruction for Chairs

[About presentation style]

The conference program will be presented as a hybrid style meeting.

An invitation email that contains information about the login will be sent to the presenters/moderators through the Zoom system. The login URL will be included in the invitation email.

At the real time webinar, the recorded lecture will be presented, and speakers/chairs are requested to join the discussion time. The presentation and Q & A session will be delivered live.

The general oral presentation time is 20 minutes. The selected Free Paper is 5 minutes.

After presentation, the discussion time (a question-and-answer session) will be held according to the moderator's instructions. The online viewer will send questions in the Q & A column. The onsite participants will ask questions using the microphone at the conference venue.

After the conference, the recorded video will be posted on the on-demand presentation page.

[For Chairs who will participate at the onsite conference venue]

Please be seated at the "next chair's seat" at least 30 minutes before the presentation. The seat will be on the left side, closest to the stage.

[For Chairs who will attend online]

Please join Zoom at least 30 minutes before your session begins.

On your entry, the secretariat will check your microphone and camera. At that time, please turn on the microphone and camera.

After checking the microphone and camera, please turn off the microphone (mute) and the camera.

Please turn on the microphone and the camera only when you are speaking. Please mute the microphone otherwise.

Please introduce the presenter at the beginning of each presentation.

Then, the secretariat will start the presentation video.

After finishing the presentation, turn on the microphone and camera again. Online viewers will send textual questions to the Q&A column, and the onsite participants will ask questions using the microphone in the conference room. So please convey those questions and moderate the discussion.

The organizer cannot handle problems such as computer operation, internet connection, video connection, and audio connection. Please solve such problems by yourself. We recommend the following environment.

-We would appreciate it if you could use a PC with as much memory as possible (CPU i5 or more, memory 8 Giga or more).

-Please connect to the Internet via a wired LAN line as much as possible.

# Instruction for Poster Presentation

## [About presentation style]

- The conference program will be presented as a hybrid style meeting.

All the speakers are requested to submit PowerPoint presentation data beforehand.

- After the conference, the presentation will be posted on the on-demand presentation page.
- Please send your presentation (PowerPoint File 4:3) in advance to the congress secretariat as follows.

- Microsoft PowerPoint (2010-2016) can be used as the application software
- File size is limited to 20 MB
- The number of PPT slides is limited to 15 slides
- Requested PowerPoint size is 4: 3
- 

## [Precautions]

- Do not post, modify, distribute, or reproduce copyrighted material, trademarks, portrait rights, or other property rights in any way without the prior written consent of the owners of these property rights.
- Regarding citations, please specify the source of the citation.
- Please exert caution regarding the protection of personal information such as name, age, surgery date, etc. This could lead to the identification of an individual.
- Please pay particular attention to images that may be considered problematic when viewed by the public at this conference.

If you have any questions, please contact the secretariat below.

Contact: APASL STC 2021 in Osaka Congress Secretariat

Email: [info@apaslstc-osaka2021.org](mailto:info@apaslstc-osaka2021.org)

Tel: +81-3-6380-0102 Fax: +81-3-6380-0103

URL <http://www.apaslstc-osaka2021.org/index.html>

## Awards

Excellent papers will be awarded as “Young Investigator Award”.

Awarding Ceremony will be held at the Closing Remark at 19:40 (JST) on September 3<sup>rd</sup>.

### Young Investigator Award (Under 40 years old)

The purpose of the “APASL STC Osaka Young Investigator Award” is to praise outstanding examples of excellence amongst those involved in research training in the early stages of their career.

## Contact

### APASL STC 2021 Osaka Scientific Secretariat

Department of Hepatology, Graduate School of Medicine, Osaka City University

Email: [thuylt@med.osaka-cu.ac.jp](mailto:thuylt@med.osaka-cu.ac.jp)

Tel: +81-6-6645-3905

### APASL STC 2021 Osaka Congress Secretariat

c/o Academia Support Japan

Email: [info@apaslstc-osaka2021.org](mailto:info@apaslstc-osaka2021.org)

Tel: +81-3-6380-0102 Fax: +81-3-6380-0103

### APASL Central Office (APASL Secretariat-Tokyo)

Asian Pacific Association for the Study of the Liver [APASL]

1-24-7-920, Shinjuku, Shinjuku-ku, Tokyo, 160-0022 Japan

Email: [apasl\\_secretariat@apasl.info](mailto:apasl_secretariat@apasl.info)

Tel: +81-3-5312-7686 Fax: +81-3-5312-7687



## Sponsors and Support Organization


The Organizing Committee of the APASL Single Topic Conference 2021 Osaka would like to express sincere gratitude to the following sponsors and organizations for supporting this conference.

### Diamond Sponsor



AbbVie GK

### Platinum Sponsor



Chugai Pharmaceutical Co., Ltd.

### Gold Sponsors



Eisai Co., Ltd.



Gilead Sciences K.K.



MSD K.K.



Otsuka Pharmaceutical Co., Ltd.

### Silver Sponsors

Actelion Pharmaceuticals Japan Ltd.	Ikuwakai Memorial Hospital
Astellas Pharma Inc.	KAN Research Institute, Inc.
Baba Memorial Hospital	Machida Gastrointestinal Hospital
Bayer Yakuhin, Ltd.	PL General Hospital
Fujirebio Co., Ltd.	Sumitomo Dainippon Pharma Co., Ltd.
Higashisumiyoshi Morimoto Hospital	Wakakusa-Daiichi Hospital

In alphabetical order

### Bronze Sponsors

Asakayama General Hospital	Mitsubishi Tanabe Pharma Corporation
ASKA Pharmaceutical Co., Ltd.	Nagayoshi General Hospital
Eli Lilly Japan K.K.	Nobelpharma Co., Ltd.
GlaxoSmithKline K.K.	Taiho Pharmaceutical Co., Ltd.
Hannan Chuo Hospital	

In alphabetical order

### Support Organizations

The Japan Society of Hepatology

The Naito Foundation

Osaka City University Alumni Association

Osaka Convention & Visitors Bureau

The Osaka Medical Research Foundation for Intractable Diseases

The Uehara Memorial Foundation

In alphabetical order

# Program at a Glance

Day 1: September 2<sup>nd</sup> (Thursday) 2021

Day	Day 1 Thursday September 2 <sup>nd</sup> 2021		
Room	Conference Hall (Onsite Venue: Room "Sakura" 5F, Hilton Osaka) (Online Venue: Zoom Webinar)	Format	Poster
AM	8:00- Registration (Onsite Venue)		Poster Free Papers Presentation Through Website
	8:30- Webinar Access Open (Virtual Venue)		
	8:55-9:00 Opening Remark	Live (Zoom)	
	9:00-10:40 Session 1 <b>Immunology, Inflammation and Regeneration in Hepato-Biliary Diseases</b> 9:00-10:10 Presentation Time	Recorded Lectures	
	10:10-10:40 Discussion Time	Live (Zoom)	
	10:50-12:30 Session 2 <b>Molecular Basis of Hepatitis B/C Virus Infection and Therapy</b> 10:50-12:00 Presentation Time	Recorded Lectures	
	12:00-12:30 Discussion Time	Live (Zoom)	
Noon	12:40-13:40 Luncheon Seminar 1 Sponsored by Eisai Co. Ltd. / MSD K.K.	Live (Zoom)	
PM	13:50-14:20 Meet the Expert 1 <b>Acute on Chronic Liver Failure</b>	Recorded Lecture	
	14:30-15:00 Meet the Expert 2 <b>COVID-19 Vaccination in Chronic Liver Diseases</b>	Recorded Lecture	
	15:10-16:50 Session 3 <b>Genetic and Epigenetic Regulation of Liver Diseases</b> 15:10-16:20 Presentation Time	Recorded Lectures	
	16:20-16:50 Discussion Time	Live (Zoom)	
	17:00-18:40 Session 4 <b>Molecular Basis of Liver Fibrosis and Cirrhosis Therapy</b> 17:00-18:10 Presentation Time	Recorded Lectures	
	18:10-18:40 Discussion Time	Live (Zoom)	
	18:50-19:50 Evening Seminar 1 Sponsored by Chugai Pharmaceutical Co., Ltd.	Live (Zoom)	

# Program at a Glance

## Day 2: September 3<sup>rd</sup> (Friday) 2021

Day	Day 2 Friday September 3 <sup>rd</sup> 2021		
Room	Conference Hall (Onsite Venue: Room "Sakura" 5F, Hilton Osaka) (Online Venue: Zoom Webinar)	Format	Poster
AM	7:30- Registration (Onsite Venue) 7:30- Webinar Access Open (Virtual Venue)		Poster Free Papers Presentation Through Website
	<u>8:00-9:00 Morning Seminar</u> Sponsored by Otsuka Pharmaceutical Co., Ltd.	Live (Zoom)	
	<u>9:10-11:10 Session 5</u> <b>Molecular Basis of Alcoholic and Nonalcoholic Steatohepatitis and Therapy</b> 9:10-10:40 Presentation Time	Recorded Lectures	
	<u>10:40-11:10 Discussion Time</u>	Live (Zoom)	
	<u>11:20-13:00 Session 6</u> <b>Use of Pluripotent Stem Cells and Reprogrammed Cells for Therapy</b> 11:20-12:30 Presentation Time	Recorded Lectures	
	<u>12:30-13:00 Discussion Time</u>	Live (Zoom)	
Noon	<u>13:10-14:10 Luncheon Seminar 2</u> Sponsored by AbbVie GK	Live (Zoom)	
PM	<u>14:20-16:20 Session 7</u> <b>Gut-Liver-Brain Axis in Hepatic Pathophysiology and Clinical Medicine</b> 14:20-15:50 Presentation Time	Recorded Lecture	
	<u>15:50-16:20 Discussion Time</u>	Live (Zoom)	
	<u>16:30-18:30 Session 8</u> <b>Diagnosis and Therapy on Hepatic and Biliary Cancer</b> 16:30-18:00 Presentation Time	Recorded Lecture	
	<u>18:00-18:30 Discussion Time</u>	Live (Zoom)	
	<u>18:40-19:40 Evening Seminar 2</u> Sponsored by Gilead Sciences K.K.	Live (Zoom)	
	<u>19:40-19:50 Closing Remark</u>	Live (Zoom)	

# Scientific Program

## Day 1: September 2<sup>nd</sup> (Thursday) 2021

### 8:55-9:00 Opening Remark

---

Dr. Norifumi Kawada (President of APASL STC Osaka)

### 9:00-10:40 Session 1: Immunology, Inflammation and Regeneration in Hepato-Biliary Diseases

*Chairs: Dr. Robert F. Schwabe (USA) / Dr. Tawesak Tanwandee (Thailand)*

- |             |  |
|-------------|--|
| 09:00-09:20 | S1-1 “Role of Hepatic Stellate Cells in Liver Cancer”<br>Dr. Robert F Schwabe (USA)  |
| 09:20-09:40 | S1-2 “Multiomics Profiling Identifies the Pro-tumoral Immune Networks in the Steatotic Tumor Microenvironment in Non-viral Hepatocellular Carcinoma”<br>Dr. Tetsuo Takehara (Japan)                                  |
| 09:40-10:00 | S1-3 “Inflammasome Modulation to Treat NASH & Liver Fibrosis”<br>Dr. Ariel Feldstein (USA)   |
| 10:00-10:05 | S1-4 “Toll-like Receptor (TLR)-3 and TLR-9 Genes Polymorphism with Hepatitis C Virus Specific Cell Immunity Outcomes in Egyptian Health-care Workers”<br>Dr. Mohamed Abdel-Samiee (Egypt)      Selected Paper #10061 |
| 10:05-10:10 | S1-5 “The New Immunological Strategy of HCC Prevention to Suppress MICA”<br>Shedding      Dr. Jun Arai (Japan)      Selected Paper #10060  |
| 10:10-10:40 | Discussion Time  |

### 10:50-12:30 Session 2: Molecular Basis of Hepatitis B/C Virus Infection and Therapy

*Chairs: Dr. Jin Mo Yang (Korea) / Dr. A. Kadir Dokmeci (Turkey)*

- |             |   |
|-------------|---|
| 10:50-11:10 | S2-1 “Being Involved in Molecular Biology for 40 Years; COVID-19 and HCC”<br>Dr. Masao Omata (Japan)      |
| 11:10-11:30 | S2-2 “Viral Quasispecies Diversity and the Outcomes of Chronic Hepatitis B”<br>Dr. Jia-Horng Kao (Taiwan) |
| 11:30-11:50 | S2-3 “Development of New Therapies for CHB-2021 and Beyond”<br>Dr. George Lau (Hong Kong)                 |



- 11:50-11:55      S2-4 **“A Robust Cell Culture System for Anti-hepatitis B Virus Drug Study via Epigenetic Reprogramming”**  
Dr. Luc Gailhouste (Japan)      Selected Paper #10022
- 11:55-12:00      S2-5 **“Zinc Chloride Enhances dsRNA-induced beta-interferon Promoter Activity through the Inhibition of Mitogen-Activated Protein Kinase Kinase 3 Expression”**  
Dr. Tatsuo Kanda (Japan)      Selected Paper #10064
- 12:00-12:30      Discussion Time

**12:40-13:40 Luncheon Seminar 1 (Sponsored by Eisai Co. Ltd. / MSD K.K.)**

*Chair: Junji Furuse (Japan)*

- 12:40-13:10      **“Consideration of the Decision Process of Treatment in Patients with Hepatocellular Carcinoma”**  
Dr. Sadahisa Ogasawara (Japan)
- 13:10-13:40      **“Clinical Outcome of Lenvatinib Therapy in Japanese Patients with Unresectable HCC”**  
Dr. Kaoru Tsuchiya (Japan)

**13:50-14:20 Meet the Expert 1**

**“Acute on Chronic Liver Failure”**  
Dr. Shiv K Sarin (India)

**14:30-15:00 Meet the Expert 2**

**“COVID-19 Vaccination in Chronic Liver Diseases”**  
Dr. Xiaolong Qi (China)

**15:10-16:50 Session 3: Genetic and Epigenetic Regulation of Liver Diseases**

*Chairs: Dr. Tetsuo Takehara (Japan) / Dr. Derek A. Mann (UK)*

- 15:10-15:30      S3-1 **“Genomic Landscape of Hepatocarcinogenesis”**  
Dr. Tatsuhiko Shibata (Japan)
- 15:30-15:50      S3-2 **“Epigenetic Changes Caused by Hepatitis C Virus Infection Persist Even after Viral Eradication and Pose a Risk of Hepatocellular Carcinoma”**  
Dr. Kazuaki Chayama (Japan)
- 15:50-16:10      S3-3 **“Epigenetic Control of Hepatic Stellate Cell Activation and Liver Fibrosis”**  
Dr. Derek A Mann (UK)

16:10-16:15 S3-4 **“COLCA1 and COLCA2, the Effector Genes Driven by rs1944919 in Primary Biliary Cholangitis (PBC) Susceptibility Locus Chromosome 11q23.1 in the Japanese Population”**

Dr. Yuki Hitomi (Japan)

Selected Paper #10002

16:15-16:20 S3-5 **“Palmitate Disrupts the Circadian Rhythm of Mitochondrial Sirtuins in Non-neoplastic Hepatocytes (PH5CH8), While it Restores the Rhythm in Hepatocellular Carcinoma Cell Line (HepG2)”**

Dr. Savera Aggarwal (India)

Selected Paper #10062

16:20-16:50 Discussion Time

**17:00-18:40 Session 4: Molecular Basis of Liver Fibrosis and Cirrhosis Therapy**

*Chairs: Dr. Jordi Gracia-Sancho (Spain) / Dr. Xiaolong Qi (China)*

17:00-17:20 S4-1 **“Treatment Strategy for Liver Fibrosis Based on Deactivation of Fibrogenic Hepatic Stellate Cells”**

Dr. Yutaka Inagaki (Japan)

17:20-17:40 S4-2 **“Molecular Basis of Portal Hypertension Therapy”**

Dr. Jordi Gracia-Sancho (Spain)

17:40-18:00 S4-3 **“Molecular Basis of Liver Fibrosis and Cirrhosis Therapy”**

Dr. Giuseppe Mazza (UK)

18:00-18:05 S4-4 **“Behavior of Reactive Cholangiocytes in the Tissue Repair Stage from Chronic Liver Injury”**

Dr. Yasuhiro Nakano (Japan)

Selected Paper #10029

18:05-18:10 S4-5 **“Capacity of Extracellular Globins in Suppression of Collagen Production from Activated Hepatic Stellate Cells via Scavenging ROS and Promoting MMP-1 Secretion”**

Dr. Vu Ngoc Hieu (Japan)

Selected Paper #10037

18:10-18:40 Discussion Time

**18:50-19:50 Evening Seminar 1: Sponsored by Chugai Pharmaceutical Co., Ltd.**

*Chair: Dr. Kiyoshi Hasegawa (Japan)*

**“A New Era of Cancer Immunotherapy in Hepatocellular Carcinoma”**

Dr. Masatoshi Kudo (Japan)

# Scientific Program

## Day 2: September 3<sup>rd</sup> (Friday) 2021

**8:00-9:00 Morning Seminar: Sponsored by Otsuka Pharmaceutical Co., Ltd.**

*Chair: Dr. Hitoshi Yoshiji (Japan)*

**“Management of Liver Cirrhosis: Summary of JSGE & JSH Evidence-based Clinical Practice Guidelines for Liver Cirrhosis 2020”**

Dr. Naoya kato (Japan)

**9:10-11:10 Session 5: Molecular Basis of Alcoholic and Nonalcoholic Steatohepatitis and Therapy**

*Chairs: Dr. Gyongi Szabo (USA) / Dr. Ekihiro Seki (USA)*

9:10-9:30 S5-1 **“Inflammasome Activation and microRNAs are Molecular Drivers and Therapeutic Targets in Steatohepatitis”**

Dr. Gyongi Szabo (USA)

9:30-9:50 S5-2 **“Treatment Targets for Nonalcoholic Steatohepatitis”**

Dr. Vincent Wong (Hong Kong)

9:50-10:10 S5-3 **“New Therapeutic Strategy for Alcoholic Liver Disease: Role of TLR7 and IL-22”**

Dr. Ekihiro Seki (USA)

10:10-10:30 S5-4 **“Molecular Basis of Alcoholic and Metabolic Steatohepatitis and Therapy”**

Dr. Jacob George (Australia)

10:30-10:35 S5-5 **“Possible Repurposing of the Analgesic Neurotrophin for NAFLD/NASH Treatment”**

Dr. Takashi Tsuchiya (USA)      Selected Paper #10014

10:35-10:40 S5-6 **“Gut-liver Axis-mediated Mechanism of NASH-associated Hepatocellular Carcinoma Progression”**

Dr. Ryota Yamagishi (Japan)      Selected Paper #10042

10:40-11:10 Discussion Time

**11:20-13:00 Session 6: Use of Pluripotent Stem Cells and Reprogrammed Cells for Therapy**

*Chairs: Dr. Atsushi Miyajima (Japan) / Dr. Diana A. Payawal (Philippines)*

- 11:20-11:40 S6-1 **“Generation of Quiescent Hepatic Stellate Cells from Human iPSCs and Development of Anti-fibrotic Drugs”**  
Dr. Atsushi Miyajima (Japan)
- 11:40-12:00 S6-2 **“Use of Pluripotent Stem Cells and Reprogrammed Cells for Therapy”**  
Dr. Lijian Hui (China)
- 12:00-12:20 S6-3 **“Generation of Human Liver using iPS Cells for Regenerative Therapies”**  
Dr. Hideki Taniguchi (Japan)
- 12:20-12:25 S6-4 **“The Therapeutic Effect of Human Placenta Mesenchymal Stem Cell-Derived Exosomes on Primary Sclerosing Cholangitis”**  
Dr. Wenyi Chen (China) Selected Paper #10063
- 12:25-12:30 S6-5 **“Kruppel-like Factor 15 Induces the Development of Mature-type Hepatocytes from Progenitor Cells”**  
Dr. Kota Tsuruya (Japan) Selected Paper #10044
- 12:30-13:00 Discussion Time

#### **13:10-14:10 Luncheon Seminar 2: Sponsored by AbbVie GK**

*Chair: Tatehiro Kagawa (Japan)*

- 13:10-13:40 **“Clinical Outcome of Antiviral Therapy in Patients with Hepatitis C Virus Infection”**  
Dr. Toshifumi Tada (Japan)
- 13:40-14:10 **“Hepatocellular Carcinoma Developing after the Eradication of Hepatitis C Virus: Surveillance, Characteristics, and Prognosis”**  
Dr. Hidenori Toyoda (Japan)

#### **14:20-16:20 Session 7: Gut-Liver-Brain Axis in Hepatic Pathophysiology and Clinical Medicine**

*Chairs: Dr. Shiv K Sarin (India) / Dr. Tatiana Kisseleva (USA)*

- 14:20-14:40 S7-1 **“IL-17 Signaling in Steatotic Hepatocytes Promotes Alcoholic Liver Disease-induced Hepatocellular Carcinoma”**  
Dr. Tatiana Kisseleva (USA)
- 14:40-15:00 S7-2 **“Gut Microbiota and Autoimmune Diseases – Type 1 Diabetes and Multiple Sclerosis –“**  
Dr. Hiroshi Ohno (Japan)

- 15:00-15:20      **S7-3 “The Liver-brain-gut Neural Reflex Maintains the Niche of Gut Regulatory T Cells”**  
Dr. Takanori Kanai (Japan)
- 15:20-15:40      **S7-4 “High-throughput Screening of New Compounds that Remove Senescent Cell Toward Prevention of HCC Development”**  
Dr. Eiji Hara (Japan)
- 15:40-15:45      **S7-5 “Nimbolide Restores Gut Dysbiosis and Prevents Bacterial Translocation by Improving Tight Junction Proteins Expression in an Experimental Hepatocarcinogenesis”**  
Dr. Balasubramanian Vairappan (India)      Selected Paper #10050
- 15:45-15:50      **S7-6 “Dysbiosis of the Gut Microbiota Associated with Plasma Levels of IFN- $\gamma$  and Viral Load in Patients with Acute Hepatitis E Infection”**  
Dr. Jian Wu (China)      Selected Paper #10054
- 15:50-16:20      Discussion Time

**16:30-18:30    Session 8: Diagnosis and Therapy on Hepatic and Biliary Cancer**

*Chairs: Dr. Masao Omata (Japan) / Dr. Jia-Horng Kao (Taiwan)*

- 16:30-16:50      **S8-1 “Whole Genomics and Precision Oncology for Hepato-Biliary Cancer”**  
Dr. Hidewaki Nakagawa (Japan)
- 16:50-17:10      **S8-2 “Biomarkers in the Treatment of Liver Cancer”**  
Dr. Naoya Kato (Japan)
- 17:10-17:30      **S8-3 “Nobel Treatment Strategy for Intermediate-stage Hepatocellular Carcinoma”**  
Dr. Masatoshi Kudo (Japan)
- 17:30-17:50      **S8-4 “HCC Surveillance in Patients with Pharmacologically Treated Viral Hepatitis”**  
Dr. Massimo Colombo (Italy)
- 17:50-17:55      **S8-5 “Analysis of Tumor Microenvironment in Patients with Advanced Hepatocellular Carcinoma Eligible for Systemic Therapy”**  
Dr. Hiroaki Kanzaki (Japan)      Selected Paper #10008
- 17:55-18:00      **S8-6 “Soluble PD-1 as a Potential Biomarker for Predicting Response to the**



**Immune Checkpoint Inhibitor in HCC Patients”**

Dr. Yutaka Yasui (Japan)

Selected Paper #10027

18:00-18:30 Discussion Time

**18:40-19:40 Evening Seminar 2: Sponsored by Gilead Sciences K.K.**

---

*Chair: Dr. Yasuhito Tanaka (Japan)*

**“Novel Agents for HBV Therapy”**

Dr. Man-Fung Yuen (Hong Kong, China)

**19:40-19:50 Closing Remark**

---

Dr. Norifumi Kawada (President of APASL STC Osaka)

# Poster Session Program

- P-01 #10028 **“Combination Therapy of Juzentaihoto and Mesenchymal Stem Cells Attenuates Liver Damage and Regresses Fibrosis in Mice”** Dr. Takahiro Iwasawa (Japan)
- P-02 #10057 **“The Anti-fibrotic Effect of *ex vivo* Expanded CD34<sup>+</sup>Cell Transplantation in a Mouse Model of NASH”** Dr. Atsutaka Masuda (Japan)
- P-03 #10056 **“Cell Membrane-mediated Direct Crosstalks between Hepatocytes and HSCs”** Dr. Inoue Kirara (Japan)
- P-04 #10009 **“Bioinformatics Study of Genes E1 and E2 from Hepatitis C Virus (HCV) with Genotypes 1, 2, 3 and 6 as Vaccine Candidates for Virus-like particles (VLPs)”** Dr. Rifaldy Fajar (Indonesia)
- P-05 #10052 **“Improvement of Liver Fibrosis in Patients Achieving a Sustained Virological Response to DAA Treatment for Hepatitis C”** Dr. Ayumi Sugiura (Japan)
- P-07 #10048 **“microRNA-6126 Reduces the Stability of NTCP Messenger RNA and Suppresses its Expression in Hepatocytes”** Dr. Koji Fujita (Japan)
- P-08 #10017 **“Molecular Characterization of Hepatitis B Virus in Young People of Vietnam”** Dr. Evgennia V. Lichnaia (Russia)
- P-09 #10043 **“Emergence of Novel Resistance-associated Substitutions against Pibrentasvir in Genotype 1b HCV-Infected Mice”** Dr. Takuro Uchida (Japan)
- P-10 #10023 **“B-cell Activating Factor Promotes Lipid Synthesis in Murine Hepatocytes”** Dr. Masanori Abe (Japan)
- P-11 #10026 **“Development of Human Hepatic Stellate Cell Activation/Deactivation Culture Condition Aiming the Liver Fibrosis Evaluation”** Dr. Seiichi Ishida (Japan)
- P-12 #10025 **“Ezetimibe Suppresses the Progression of NASH and NASH-associated HCC”** Dr. Kouichi Miura (Japan)
- P-13 #10038 **“Analysis of Liver Fibrosis Progression, Lipid Profile, and Atherosclerosis in NAFLD”** Dr. Shun-ichi Wakabayashi (Japan)
- P-14 #10030 **“Glycine Ameliorates Steatohepatitis via Reduction of Oxidative Stress in Hepatocyte-specific PTEN-deficient Mice”** Dr. Kazuyoshi Kon (Japan)
- P-15 #10015 **“Synergistic Regulation of Hepatic Fsp27b Expression by HNF4 $\alpha$ ; and CREBH”** Dr. Ichiro C. Kasano-Camones (Japan)
- P-16 #10040 **“A Novel Isolation Method of Hepatic Stellate Cells from Tumor Tissue of Obesity-associated Hepatocellular Carcinoma”** Dr. Yi Cheng (China)
- P-17 #10036 **“Type IV Collagen 7S is the Most Accurate test for Identifying Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease with Type 2 Diabetes”** Dr. Hiroshi Ishiba (Japan)
- P-18 #10055 **“Systemic Inflammation Predict 30-day Bacterial Infection Post-liver Transplantation”** Dr. Jiong Yu (China)
- P-19 #10021 **“Elevated Alpha Fetoprotein in the Absence of Hepatic Malignancy in a Patient with Acute Hepatitis”** Dr. Jacklyn M So-Cabahug (Philippines)
- P-20 #10005 **“Nanoparticle-mediated Delivery of 2-deoxy-D-glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice”** Dr. Sohji Nishina (Japan)

- P-21 #10033 **“The Complication Rate and Clinical Significance of Extrahepatic Autoimmune Diseases (EHAIDs) in Primary Biliary Cholangitis (PBC)”**  
Dr. Yuki Yamashita (Japan)
- P-22 #10058 **“Role of CD40 in Hepatocellular Carcinoma”**  
Dr. Vinh Hanh Ngo (Japan)
- P-23 #10049 **“Changes of Soluble Immune Checkpoint Proteins following Antiviral Treatment in Chronic Hepatitis C Patients and the Roles of the CD27-CD70 Pathway in Hepatocellular Carcinoma Development”**  
Dr. Minh Phuong Dong (Japan)
- P-24 #10012 **“Case Report of Overlap Syndrome: Autoimmune Hepatitis and Primary Biliary Cholangitis, a Vietnamese Patient Diagnosing by pathology”**  
Dr. Lieu Quang Dau (Viet Nam)
- P-25 #10051 **“Functional Analysis of Liver Cirrhosis-associated Gut Microbiota Uncovers a Unique Mechanism of Hyperammonemia in Hepatic Encephalopathy”**  
Dr. Tomonori Kamiya (Japan)
- P-26 #10035 **“Role of the FibroScan-aspartate Aminotransferase Score in Risk Stratification for a Japanese Cohort with Fatty Liver Diseases”** Dr. Hideki Fujii (Japan)
- P-27 #10039 **“Possible Involvement of ZNF641 with the Prognosis of Hepatocellular Carcinoma”**  
Dr. Hirayuki Enomoto (Japan)
- P-28 #10004 **“The Long Non-coding RNA of RMRP is Repressed by PERK and Induces Apoptosis in Hepatocellular Carcinoma”**  
Dr. Atsushi Yukimoto (Japan)
- P-29 #10011 **“Identifying UGT1A1 Gene Mutations in Vietnamese Patients with Gilbert Syndrome”**  
Dr. Lieu Quang Dau (Viet Nam)
- P-30 #10020 **“Validation of Platelets - Albumin - Bilirubin (PALBI) Score for Predicting Overall Survival of Hepatocellular Carcinoma at Hanoi Medical University Hospital, Vietnam”**  
Dr. Bich Hang Doan (Viet Nam)
- P-31 #10016 **“Validation of ABCR and ART for Predicting Overall Survival in Patient with Hepatocellular Carcinoma Treated with Transarterial Chemoembolism in Hanoi Medical University Hospital, Vietnam”**  
Dr. Duc Minh Pham (Viet Nam)
- P-32 #10024 **“A Novel Anticancer Therapy with Deferoxamine and Drugs Targeting Iron-chelation-Modulated Metabolism”**  
Dr. Koichi Fujisawa (Japan)
- P-33 #10059 **“Identification of Key Modules and Hub Genes Involved in Cholangiocarcinoma Progression and Prognosis”**  
Dr. Qigu Yao (China)
- P-34 #10031 **“PD-L1 Promotes Cell Proliferation in Liver Cancer Cells”**  
Dr. Toshimitsu Tanaka (Japan)
- P-35 #10003 **“Efficacy of Zinc Acetate in HCC Cell Lines via the Induction of Apoptosis”**  
Dr. Takashi Himoto (Japan)
- P-36 #10007 **“Liver Piopsy Technique in the Era of Cancer Genomic Therapies: A Single Center Retrospective Analysis”**  
Dr. Naoya Kanogawa (Japan)
- P-37 #10041 **“Intracellular Gaps Formation of Liver Sinusoidal Endothelial Cells Facilitates Cancer Cell Engraftment in Liver”**  
Dr. Truong Huu Hoang (Japan)

P-38 #10045 **“Role of SKI in the Suppression of Cholangiocarcinoma Cell Proliferation by Inducing G1-phase Arrest: Validation of Results from Clinical Specimens”**

Dr. Etsushi Kawamura (Japan)

P-39 #10034 **“The Association between Plasma Free Amino Acids and Sarcopenia in the Course of Hepatocellular Carcinoma Recurrence”**

Dr. Shunichi Tsuge (Japan)

P-40 #10010 **“A Survey on Approaches towards Patients with Elevated Liver Enzymes before Surgery in Different Vietnamese Hospitals”**

Dr. Hang Dao (Viet Nam)

